Lakefront Biotherapeutics | GLPG - Cost Of Sales


Lakefront Biotherapeutics reported EUR4.8M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
argenx SE USD 121M 28.69M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Biogen USD 797.5M 302M Mar/2026
Genmab DKK 81M 23M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
GRIFOLS EUR 1.08B 214.82M Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Incyte USD 104.5M 16.68M Mar/2026
Merck EUR 2.07B 219M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026